Tags
- 24 Weeks
- 3
- 9
- A
- AD 73
- Administration
- Adriatic
- Adult
- Advanced
- Advent
- Advent of...
- Agriculture in the United States
- Ahn Mj
- Alive
- An
- Application
- Approval
- Approved
- Avenue
- Avenues
- Based on
- Being
- Binimetinib
- Biologic
- Biologics license application
- Biopharmaceutical
- Breakthrough
- Breakthrough therapy
- BTD
- Cancer
- Cancer Institute
- Carcinogenesis
- Catarata
- CCRT
- Cell
- Central Commission for Discipline Inspection
- Chemoradiotherapy
- China
- CLIN
- Clinical
- Clinical endpoint
- Clinical Lung Cancer
- Clinical trial
- Cohort
- Combination
- Commission
- Concurrency
- Confidence
- Confidence interval
- Considered
- Correction
- Cycles
- Danger/Disease Control
- Data
- DCR
- Death
- Designation
- Development
- Disease
- Disease progression
- Dor Wa
- Driver
- Drug
- Duration
- Durvalumab
- Ef Ahn
- Encorafenib
- Endpoint
- Endpoints
- Estimation
- E.T.
- European
- European Commission
- Expeditus
- Experienced
- Fabre
- FAQ
- FDA
- Following
- Follows
- Food
- Food and Drug Administration
- Frequently
- Gj Smit
- Grant
- Grants
- Guangdong
- Hazard
- Hazard ratio
- Hospital
- Human subject research
- Inhibition
- Inhibitor
- Interval
- IRRC
- J
- Journal of Clinical Oncology
- Kraš
- Laboratory
- Lee Gw
- Lethality
- License
- Life-threatening conditions
- Lung cancer
- M
- Medical
- Medicine
- Metástasis
- Mutation
- Mutations
- New
- New Medicine
- New Medicines
- Nine Months
- Non-small-cell lung carcinoma
- Normal distribution
- Okamoto
- Once a Day
- Oncol Park
- Open-label trial
- Os Hazard
- P
- Patient
- PFS
- Pharmaceutical drug
- Pharos
- Phase
- Phase II
- Phase III
- Phases of clinical research
- Placebo
- Placebo-controlled study
- PLU
- Positive
- Precision
- Precision medicine
- Primary
- Priority
- Priority review
- Product
- Professor
- Prognosis
- Progressed
- Progression
- Progression-free survival
- Provincial
- Publishing
- Radiology
- Randomness
- Rationale
- Reduce
- Reduction
- Regulation
- Regulatory review
- Resistance
- Response rate
- Result
- Review process
- Risk
- Safety
- SCLC
- Secondary
- Secondary endpoints
- Small cell
- Small-cell carcinoma
- Smit Ef
- Supplement
- Survival
- Survival rate
- Systemic
- Systemic therapy
- Target
- The Advent
- The european
- The independent
- The national
- Therapy
- The trial
- Treat
- Tremelimumab
- Trial
- Twice
- Versus
- Who